Financing, Equity Capital Markets

Boundless Bio, Inc.

03/24
|
$100.0 Million
Boundless Bio, Inc.
Piper Sandler served as bookrunner for Boundless Bio, Inc. on its initial public offering
Sub-Type
IPO
Sector
Healthcare
Sub-Sector
Biopharma

Related Transactions

All Transactions
$150.0 Million
EverBank
EverBank Financial Corp.
Subordinated Notes Offering
Sole Underwriter
Northpointe
Northpointe Bancshares, Inc.
Subordinated Notes Offering
Sole Placement Agent
miax
warburg pincus
Miami International Holdings, Inc.
Miami International Holdings, Inc received a strategic growth investment from Warburg Pincus
Financial Advisor
$42.0 Million
Trinitas
Trinitas Capital Management, LLC
Senior Unsecured Notes Offering
Sole Placement Agent
$103.2 Million
Merchants Bancorp
Merchants Bancorp
Confidentially Marketed Follow-On Offering
Passive Bookrunner
$70.0 Million
CereVasc
Bain
Xontogeny
CereVasc, Inc.
CereVasc, Inc. has received a Series B Financing from Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund (PXV)

Financial Advisor
$225.0 Million
Provident Financial Services, Inc.
Provident Financial Services Inc.
Subordinated Notes Offering
Left Bookrunner
$184.7 Million
Skyward Specialty Insurance
Skyward Specialty Insurance
Follow-On Offering
Passive Bookrunner
$100.0 Million
Context Therapeutics LLC
Context Therapeutics LLC
PIPE
Sole Placement Agent
$50.0 Million
Legion
Riverwood
Legion Technologies, Inc.
Legion Technologies, Inc. has received a growth investment from Riverwood Capital Management L.P.
Financial Advisor
$201.2 Million
Nurix Inc.
Nurix Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$150.0 Million
Blue Ridge Bankshares
Blue Ridge Bankshares, Inc.
PIPE
Sole Placement Agent
$100.0 Million
Boundless Bio, Inc.
Boundless Bio, Inc.
Initial Public Offering
Active Bookrunner
$200.0 Million
Praxis Precision Medicines
Praxis Precision Medicines, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$75.0 Million
Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner
$600.0 Million
Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc.
Confidentially Marketed Follow-On Offering
Active Bookrunner

© 2024 Piper Sandler Companies. Since 1895. All rights reserved.